AU2019340173B2 - Imidazopyridinone compound - Google Patents
Imidazopyridinone compound Download PDFInfo
- Publication number
- AU2019340173B2 AU2019340173B2 AU2019340173A AU2019340173A AU2019340173B2 AU 2019340173 B2 AU2019340173 B2 AU 2019340173B2 AU 2019340173 A AU2019340173 A AU 2019340173A AU 2019340173 A AU2019340173 A AU 2019340173A AU 2019340173 B2 AU2019340173 B2 AU 2019340173B2
- Authority
- AU
- Australia
- Prior art keywords
- reference example
- methyl
- mixture
- alkyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018-171839 | 2018-09-13 | ||
| JP2018171839 | 2018-09-13 | ||
| PCT/JP2019/035792 WO2020054788A1 (ja) | 2018-09-13 | 2019-09-12 | イミダゾピリジノン化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019340173A1 AU2019340173A1 (en) | 2021-04-08 |
| AU2019340173B2 true AU2019340173B2 (en) | 2024-02-08 |
Family
ID=69777067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019340173A Ceased AU2019340173B2 (en) | 2018-09-13 | 2019-09-12 | Imidazopyridinone compound |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US12077531B2 (https=) |
| EP (1) | EP3808747B1 (https=) |
| JP (1) | JP7458987B2 (https=) |
| KR (1) | KR102830577B1 (https=) |
| CN (1) | CN112689637B (https=) |
| AR (1) | AR116400A1 (https=) |
| AU (1) | AU2019340173B2 (https=) |
| BR (1) | BR112021004730A2 (https=) |
| CA (1) | CA3106385A1 (https=) |
| DK (1) | DK3808747T3 (https=) |
| ES (1) | ES3016010T3 (https=) |
| FI (1) | FI3808747T3 (https=) |
| HU (1) | HUE069830T2 (https=) |
| IL (1) | IL281391B2 (https=) |
| MX (1) | MX2021003027A (https=) |
| MY (1) | MY207239A (https=) |
| NZ (1) | NZ773786A (https=) |
| PH (1) | PH12021550512A1 (https=) |
| PL (1) | PL3808747T3 (https=) |
| PT (1) | PT3808747T (https=) |
| SG (1) | SG11202102441VA (https=) |
| TW (1) | TWI814903B (https=) |
| WO (1) | WO2020054788A1 (https=) |
| ZA (1) | ZA202101671B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025264818A1 (en) * | 2024-06-20 | 2025-12-26 | Raythera, Inc. | Stat6 modulators and methods of uses thereof |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7414550B2 (ja) * | 2020-01-23 | 2024-01-16 | キッセイ薬品工業株式会社 | （ヘテロ）アリールイミダゾロン化合物 |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| CA3169000A1 (en) * | 2020-03-11 | 2021-09-16 | Hideki Takeuchi | Crystal of imidazopyridinone compound or salt thereof |
| JP7654426B2 (ja) * | 2020-03-12 | 2025-04-01 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物の製造方法 |
| CN117402178B (zh) * | 2023-12-15 | 2024-03-08 | 英矽智能科技(上海)有限公司 | 作为jak抑制剂和phd抑制剂的嘧啶类化合物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009134750A1 (en) * | 2008-04-28 | 2009-11-05 | Janssen Pharmaceutica Nv | Benzoimidazoles as prolyl hydroxylase inhibitors |
| WO2009137291A2 (en) * | 2008-05-08 | 2009-11-12 | Merck & Co., Inc. | Spiroazaindoles |
| US20110077267A1 (en) * | 2009-07-17 | 2011-03-31 | Japan Tobacco Inc. | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent |
| US20120322772A1 (en) * | 2005-04-28 | 2012-12-20 | Bayer Intellectual Property Gmbh | Substituted imidazopyrimidines and triazolopyrimidines |
| WO2016148306A1 (en) * | 2015-03-18 | 2016-09-22 | Takeda Pharmaceutical Company Limited | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650961B1 (de) * | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| CA2344249A1 (en) * | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | Pyrrolopyrimidines as protein kinase inhibitors |
| WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
| MXPA06000700A (es) * | 2003-07-23 | 2006-04-11 | Wyeth Corp | Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6. |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| ATE531705T1 (de) * | 2004-05-18 | 2011-11-15 | Schering Corp | Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren |
| EP1861377B1 (en) | 2005-03-15 | 2010-12-29 | Pfizer, Inc. | Benzimidazolone derivatives as cb2 receptor ligands |
| WO2007015877A2 (en) * | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
| US20070142369A1 (en) | 2005-12-21 | 2007-06-21 | Margaret Van Heek | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
| US20090298811A1 (en) | 2006-09-12 | 2009-12-03 | Pfizer Inc | Benzimidazolone derivatives |
| EP2160187B1 (en) | 2007-05-16 | 2013-05-22 | Merck Sharp & Dohme Corp. | Spiroindalones |
| CA2686485A1 (en) * | 2007-05-23 | 2008-11-27 | Pharmacopeia, Llc | Purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| CA2698071A1 (en) | 2007-08-27 | 2009-03-05 | Wyeth Llc | Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| CN101951777A (zh) * | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢呋喃并吡啶酮 |
| EP2364313B1 (en) | 2008-09-09 | 2014-01-08 | Boehringer Ingelheim International GmbH | Aza-benzimidazolone chymase inhibitors |
| JP2011037814A (ja) | 2009-08-14 | 2011-02-24 | Synstar Japan Co Ltd | マラリア原虫疾患予防又は治療用の５−ヘテロ環置換イミノ−９−ジアルキルアミノベンゾ［ａ］フェノキサチン化合物又はその塩とアーテミシニン誘導体との組み合わせ |
| WO2011096490A1 (ja) | 2010-02-04 | 2011-08-11 | 第一三共株式会社 | イミダゾピリジン－２－オン誘導体 |
| FR2967355B1 (fr) * | 2010-11-17 | 2013-09-27 | Jouvin Jean Luc | Seringue dentaire securisee |
| WO2014181813A1 (ja) | 2013-05-10 | 2014-11-13 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3056975B1 (en) | 2013-10-08 | 2020-08-12 | Maxell, Ltd. | Projection type image display device, manipulation detection device and projection type image display method |
| WO2015052675A1 (en) | 2013-10-10 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Substituted dihydro-benzimidazole compounds as ror gamma modulators |
| CN104926733B (zh) | 2014-03-18 | 2019-05-10 | 北京韩美药品有限公司 | 作为RORγ调节剂的化合物 |
| UA124090C2 (uk) * | 2015-06-03 | 2021-07-21 | Прінсіпіа Байофарма Інк. | Інгібітори тирозинкінази |
| EP3414234B1 (en) | 2015-10-14 | 2022-06-29 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| RU2743126C9 (ru) | 2016-08-22 | 2021-04-27 | Шицзячжуан Сагесити Нью Драг Дивелопмент Ко., Лтд. | Ингибитор pde4 |
| US10899758B2 (en) * | 2016-09-16 | 2021-01-26 | Vitae Pharmaceuticals, Llc | Inhibitors of the menin-MLL interaction |
| CA3087886A1 (en) * | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
-
2019
- 2019-09-12 JP JP2020546064A patent/JP7458987B2/ja active Active
- 2019-09-12 US US17/268,011 patent/US12077531B2/en active Active
- 2019-09-12 NZ NZ773786A patent/NZ773786A/en unknown
- 2019-09-12 CA CA3106385A patent/CA3106385A1/en active Pending
- 2019-09-12 SG SG11202102441VA patent/SG11202102441VA/en unknown
- 2019-09-12 KR KR1020217004504A patent/KR102830577B1/ko active Active
- 2019-09-12 EP EP19859445.9A patent/EP3808747B1/en active Active
- 2019-09-12 ES ES19859445T patent/ES3016010T3/es active Active
- 2019-09-12 HU HUE19859445A patent/HUE069830T2/hu unknown
- 2019-09-12 BR BR112021004730-1A patent/BR112021004730A2/pt unknown
- 2019-09-12 DK DK19859445.9T patent/DK3808747T3/da active
- 2019-09-12 CN CN201980059004.8A patent/CN112689637B/zh active Active
- 2019-09-12 FI FIEP19859445.9T patent/FI3808747T3/fi active
- 2019-09-12 MX MX2021003027A patent/MX2021003027A/es unknown
- 2019-09-12 MY MYPI2021001303A patent/MY207239A/en unknown
- 2019-09-12 IL IL281391A patent/IL281391B2/en unknown
- 2019-09-12 AU AU2019340173A patent/AU2019340173B2/en not_active Ceased
- 2019-09-12 WO PCT/JP2019/035792 patent/WO2020054788A1/ja not_active Ceased
- 2019-09-12 PT PT198594459T patent/PT3808747T/pt unknown
- 2019-09-12 PL PL19859445.9T patent/PL3808747T3/pl unknown
- 2019-09-12 TW TW108133054A patent/TWI814903B/zh active
- 2019-09-13 AR ARP190102601A patent/AR116400A1/es unknown
-
2021
- 2021-03-10 PH PH12021550512A patent/PH12021550512A1/en unknown
- 2021-03-11 ZA ZA2021/01671A patent/ZA202101671B/en unknown
-
2024
- 2024-07-24 US US18/782,102 patent/US20240425504A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120322772A1 (en) * | 2005-04-28 | 2012-12-20 | Bayer Intellectual Property Gmbh | Substituted imidazopyrimidines and triazolopyrimidines |
| WO2009134750A1 (en) * | 2008-04-28 | 2009-11-05 | Janssen Pharmaceutica Nv | Benzoimidazoles as prolyl hydroxylase inhibitors |
| WO2009137291A2 (en) * | 2008-05-08 | 2009-11-12 | Merck & Co., Inc. | Spiroazaindoles |
| US20110077267A1 (en) * | 2009-07-17 | 2011-03-31 | Japan Tobacco Inc. | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent |
| WO2016148306A1 (en) * | 2015-03-18 | 2016-09-22 | Takeda Pharmaceutical Company Limited | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| Wu, Yue, et al. "Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy." MedChemComm, 2016, 7(7), p 1271-1284. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025264818A1 (en) * | 2024-06-20 | 2025-12-26 | Raythera, Inc. | Stat6 modulators and methods of uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019340173B2 (en) | Imidazopyridinone compound | |
| AU2020214404B2 (en) | Immunomodulators, compositions and methods thereof | |
| EP3652164B1 (en) | Phenylacetamides as inhibitors of rock | |
| RU2638540C1 (ru) | Ингибиторы днк-пк | |
| TW201726619A (zh) | 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物 | |
| IL285354A (en) | prc2 inhibitors | |
| CN109810041A (zh) | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 | |
| CA3007280A1 (en) | Apelin receptor agonists and methods of use | |
| EP4423068B1 (en) | Rxfp1 agonists | |
| CA3145111C (en) | Tricyclic compound, preparation method therefor and use thereof | |
| CA3081424A1 (en) | Spirocyclic compounds as farnesoid x receptor modulators | |
| JP6859358B2 (ja) | テトラヒドロインダゾール及びその医学的使用 | |
| TW202229273A (zh) | 稠合雜芳基化合物及其作為CaMKII抑制劑之用途 | |
| JP7504822B2 (ja) | イミダゾピリジノン化合物を含む医薬組成物 | |
| CN121889385A (zh) | 作为因子b抑制剂的2-(1h-吲哚-4-基)甲基)2h-吲唑衍生物 | |
| RU2776844C1 (ru) | Соединение имидазопиридинона | |
| JP7654426B2 (ja) | イミダゾピリジノン化合物の製造方法 | |
| JP7414550B2 (ja) | （ヘテロ）アリールイミダゾロン化合物 | |
| HK40050961A (en) | Imidazopyridinone compound | |
| HK40050961B (zh) | 咪唑并吡啶酮化合物 | |
| JP2016108257A (ja) | インドリン誘導体 | |
| JP7231610B2 (ja) | インドール誘導体及びその使用 | |
| HK1249502B (zh) | 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |